The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

The approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...

Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...

Bausch + Lomb said enVista Envy intraocular lenses will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. The company is in the process of seeking ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has ...

Cataracts, a common eye condition that clouds vision and hampers daily activities, can now be treated with innovative ...

There are several types of IOLs available, each designed to meet different visual needs. Monofocal lenses correct vision at a single distance, while multifocal lenses provide clarity at multiple ...

Intraocular lens choice, as facilitated by the surgeon, can connect the patient with the appropriate device for their ...